Clinical Trials
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0720
Phase II ERCC 1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
Research Committee(s)
Lung Cancer
Activated
11-15-2008
Closed
05-15-2012
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0711
Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction."
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
10-15-2008
ClinicalTrials.gov Registry Number
NCT00608361
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0307A
Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)
Research Committee(s)
Breast Cancer
Activated
10-01-2008
Closed
02-01-2010
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0629
Observational study of asymptomatic Waldenström’s Macroglobulinemia and Phase II study of tandem autologous transplant and maintenance treatment for patients with symptomatic disease
Research Committee(s)
Myeloma
Activated
09-15-2008
Closed
Phase
Accrual
4%
SWOG Clinical Trial Number
S0717
A Phase I and A Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) with or without MEDI-522 (NSC-719850)
Research Committee(s)
Genitourinary Cancer
Activated
06-15-2008
Closed
04-01-2009
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0000D
S0000D, "A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT, Phase III Ancillary to S0000-SELECT
Activated
06-03-2008
Closed
05-28-2013
ClinicalTrials.gov Registry Number
NCT00706121
Closed
Phase
Accrual
2%
Published
SWOG Clinical Trial Number
S0502
A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2008
Closed
10-01-2009
ClinicalTrials.gov Registry Number
NCT00324987
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0777
A Randomized Phase III Trial of CC-5013 (lenalidomide, NSD-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant
Status Notes
Revision #24 requires sites to contact all patients that have been enrolled, including those that have completed treatment and follow-up, to offer them participation in extended follow-up.
Research Committee(s)
Myeloma
Activated
04-01-2008
Closed
02-01-2012
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0727
A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
03-01-2008
Closed
09-01-2010
ClinicalTrials.gov Registry Number
NCT00617708
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0518
Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Research Committee(s)
Gastrointestinal Cancer
Activated
12-01-2007
Closed
09-01-2012
ClinicalTrials.gov Registry Number
NCT00569127
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0535
A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Research Committee(s)
Leukemia
Activated
11-15-2007
ClinicalTrials.gov Registry Number
NCT00551460
Closed
Phase
Accrual
91%
Published
SWOG Clinical Trial Number
S0438
A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma
Research Committee(s)
Melanoma
Activated
08-01-2007
Closed
11-15-2009
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0337
A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer
Research Committee(s)
Genitourinary Cancer
Activated
07-15-2007
Closed
08-15-2012
ClinicalTrials.gov Registry Number
NCT00445601
Closed
Phase
Accrual
95%
SWOG Clinical Trial Number
S0635
A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features
Research Committee(s)
Lung Cancer
Activated
07-15-2007
Closed
08-15-2011
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0636
A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas
Research Committee(s)
Lung Cancer
Activated
07-15-2007
Closed
09-01-2010
Closed
Phase
Accrual
11%
Published
SWOG Clinical Trial Number
S0600
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX
Research Committee(s)
Gastrointestinal Cancer
Activated
06-15-2007
Closed
11-10-2010
ClinicalTrials.gov Registry Number
NCT00499369
Closed
Phase
Accrual
19%
Published
SWOG Clinical Trial Number
S0521
A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
Research Committee(s)
Leukemia
Activated
06-01-2007
ClinicalTrials.gov Registry Number
NCT00492856
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0354
A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
04-01-2007
Closed
05-15-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0622
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Research Committee(s)
Breast Cancer
Activated
03-15-2007
Closed
12-15-2010
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0353
Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Research Committee(s)
Genitourinary Cancer
Activated
11-15-2006
Closed
10-15-2009